A survey to evaluate the extent to which national recommendations on brand name prescribing of all biological DMARDS including biosimilars are used to manage rheumatological conditions within acute trusts in the UK are being complied with.

Assessment of Brand Name Prescribing of Biologics (IRAS Ref. 226131) Contacts

Surface Mail

Drug Safety Research Unit,
Bursledon Hall,
Blundell Lane,
SO31 1AA, U.K.


Alison Evans

Alison Evans

Study Manager

Email: Alison.Evans@dsru.org

Tel: 02380 408615

Jacqueline  Denyer

Jacqueline Denyer

Study Administrator

Email: Jacqueline.Denyer@dsru.org

Tel: 02380 408282